Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Baylor College of Medicine, Houston
Platelet glycoprotein mutation is critical in von Willebrand factor binding to platelets
November 4th, 2005
A study from the United States has described the gain of von Willebrand factor (VWF)-binding function by mutagenesis of a species-conserved residue within the Leu-rich repeat (LRR) region of platelet glycoprotein (GP) Ib alpha. "GP Ib alpha, a member of the LRR protein family, mediates platelet adhesion to immobilized VWF. We investigated the role in VWF binding of charged residues in the LRR region of GP lb alpha that are conserved in human, canine, and murine proteins," wrote Y.D. Peng and colleagues, Baylor College of Medicine. "Substitution of His-86 with either Ala or Glu resulted in a gain of VWF-binding function as judged by increased VWF...
Source: Biotech Law Weekly (2005-11-04)
|
